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Summary The extent of primary surgery for breast cancer could be tailored to the patient if previous information on the presence or absence
of lymph node involvement could be reliably determined. Prospective radioimmunoscintigraphy in 29 patients with primary breast cancer that
was found on screening has been undertaken with 555 MBq (15 mCi) 99mTc SM3, an Imperial Cancer Research Fund (ICRF) murine
monoclonal antibody, 0.5 mg with images at 10 min and 22 h, and analysis using a change detection algorithm. Sites of significant change
between the early and later images were displayed as a map of probabilities. Image-positive and -negative axillary lymph nodes were
compared by histology in the 28 evaluable patients. The correct identification of the presence or absence of node involvement, even if
impalpable, has been shown in 24 out of 28 patients (29 lymph node groups). Sensitivity was 90% (nine out often), specificity 84% (16 out of
19) and accuracy 86%. These results encourage further assessment of this technique.
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Surgeons have become more conservative in their approach
towards patients with breast cancer. The introduction ofsegmental
mastectomy as a valid surgical option, combined with the
mammographic detection ofearly, small cancers of the breast, has
led to questioning the need for axillary lymph node dissection in
every patient.
Some surgeons feel thataxillary lymph node dissection shouldbe
performed in all patients with breast cancer to stage the disease and
to guarantee local control in the axillae and believe that it has a
prognostic andtherapeutic role (Harris andOsteen, 1985). Selection
for chemotherapy is based on axillary node status. Surgery is
currently the only reliable way ofassessing nodal disease; unfortu-
nately, to obtain this information, those women with node-negative
disease receive unnecessarily extensive surgery. Another group of
surgeons consider that axillary lymph node dissection has only a
prognostic aim. Although it is important to take away the axillary
lymph nodes that are macroscopically infiltrated by tumour, they
consider that micrometastases do not produce recurrence in the
axilla oraffect overall survival (Fisher et al, 1985).
Axillary lymph node dissection has already been abandoned for
ductal carcinoma in situ (DCIS) because ofthe extremely low rate
of lymph node metastases (Deckers, 1991). Routine node dissec-
tion for lesions larger than DCIS but with extremely low likeli-
hood of axillary node involvement could also be abandoned,
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particularly if a preoperative imaging technique were available to
tailor the extent ofaxillary surgery to the individual woman.
Radioimmunoscintigraphy has been used with success in the
management of some neoplasms in specific clinical conditions
(Britton and Granowska, 1987; Bischof Delaloye et al, 1989;
Doerr et al, 1990; Massuger et al, 1990; Wahl, 1992; Britton et al,
1993; Granowska et al, 1993), but it is limited by low tumour to
background ratio, low percentage of injected dose per gram taken
up by the tumour and heterogeneity of expression of the antigen.
To overcome these problems, a change detection algorithm has
been applied to detect small changes with time in antibody uptake.
This exploits the kinetics of the antibody, whose specific uptake
increases with time, whereas non-specific uptake decreases with
time after an initial distribution.
The aim of this study is to evaluate technetium-99m-labelled
SM3 (stripped mucin 3), a monoclonal antibody produced by the
Imperial Cancer Research Fund, for the purpose of evaluating
preoperatively axillary lymph node involvement in patients with
breast cancer that was found by a screening programme.
MATERIALS AND METHODS
Patients
A total of 29 women with recently diagnosed breast cancer from
the national screening programme were studied. Their age ranged
between 34 and 84 years (median 58 years). All had previous
clinical examination, mammography, and fine-needle aspiration
cytology (FNAC); some also had previous breast ultrasound (US)
and excisional biopsy. All were preoperative patients and had
given signed informed consent, after the Royal Hospitals Trust
Ethics committee requirements.
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Monoclonal antibody
SM3, an IgGI subclass murine monoclonal antibody, is one ofthe
new antibodies that are reactive with the protein core of the poly-
morphic epithelial mucin (PEM) series of antigens in the ducts of
the breast. It binds specifically to the partially deglycosylated
mucin that is typical ofthe cancer cells (Girling et al, 1989) and is
usually unreactive with the fully processed mucin produced by the
normal and lactating mammary gland (Burchell et al, 1987). An
immunohistochemical study of breast tumours and tissues has
shown that the SM3 antibody reacts strongly with the majority of
primary breast cancers (91%) but shows little or no reaction with
benign breast tumours, resting or lactating breast and most normal
tissues (Burchell and Taylor-Papadimitriou, 1993). In normal
breast epithelial cells, the SM3 epitope is masked by the carbo-
hydrate side-chains.
The radiolabel
Technetium-99m forms stable complexes with sulphur-containing
compounds and can be made to bind to the sulphur-containing
amino acids in the immunoglobulin. Normally, these thiol groups
are .in the oxidized, disulphide form and are unavailable for
labelling. However, in the presence of mild reducing conditions,
free thiols can be exposed to form a stable complex with
technetium-99m (Mather and Ellison, 1990).
The antibody was concentrated by ultrafiltration to approxi-
mately 1O mg ml'. To a stirred solution of antibody, sufficient
2-mercaptoethanol was added to provide a molar ratio of 1000:1
2-mercaptoethanol-antibody. The mixture was incubated at room
temperature for 30 min with continuous rotation, and the reduced
antibody was purified by gel filtration on Sephadex-G50 using
phosphate-buffered saline as a mobile phase. The antibody frac-
tions were collated and divided into 0.5-mg aliquots. These were
frozen immediately at-10°C and stored for further use.
When imaging was required, an antibody aliquot was thawed
and an Amerscan methylene diphosphonate, MDP, kit was recon-
stituted with 5 ml of 0.9% sterile saline. An aliquot (50 ,l) of
MDP solution was added, followed by 99mTc pertechnetate, 16 mCi
(600 MBq) to the antibody/MDP mixture, which was gently
shaken for 10 min. The labelling efficiency was assessed by thin-
layer chromatography (ITLC) developed in 0.9% saline and
confirmed to be over 95%. The labelled antibody is stable up to 24
hours in vitro after preparation. The antigen-binding ability of the
radiolabelled antibody was compared to the unlabelled starting
material (relative immunoreactivity) by testing with an enzyme-
linked immunosorbent assay (ELISA). The average value was
75%. The technetium-99m-labelled antibody is stable in vivo.
There was no thyroid uptake of 99mTc even after 24 h in patients
who had received no thyroid blocking medication.
Injection and acquisition
The radiopharmaceutical [15 mCi (555 MBq), 0.5 mg in I ml] was
injected in the antecubital vein of the arm opposite the lesion. Early
images were acquired 10 min after the injection and included both
breasts, both axillae, the heart and major vessels and part ofthe liver.
After making small indelible ink marks on the skin, tiny 57Co sources
(Amersham International) were positioned on the sternal notch,
xiphisternum, axillary tail of both breasts and lower costal margins
on the hemiclavicular line. The gamma-camera (Siemens Orbiter75)
with a low-energy, parallel-hole general-purpose collimator was
linked to a Micas V computer (Park Medical). The camera was
peaked on 122 keV with a 15% window and an image was acquired
for 60 s. The position of each marker was recorded on a blank film
superimposed on the screen ofthe computer before the beginning of
the acquisition; this helped in the repositioning of the camera the
following day for the 24 h images. Another picture was acquired for
60 s with the patient wearing a flexible lead strip giving the inferior
outlines ofthe breasts and with cobalt markers corresponding to both
nipples. The main image of the patient lying in the same position,
with the markers and the breast outline off, was acquired with the
camera set on the technetium-99m 140-keV peak with a 15%
window. Acquisition stopped at 800 Kcounts (2000 Kcounts in the
last eight patients). This image was used as a template in the
processing with thechange detection algorithm, demonstrating initial
vascular and non-specific activity. The other two images provided
anatomical references to aid in the registration of the 10-min and
22-h images. A right lateral and a left lateral picture of the upper
chest and axilla were also acquired for 500 Kcounts. These images
were taken to have a further confirmation of the presence of any
lesion, and were preceded by a picture with 57Co skin markers posi-
tioned on the axillary tail, xiphisternum, inferior costal margin and
posterior aspect ofthe axilla with the camera settings and acquisition
as before. For all images the matrix size was 256 x 256.
At 22 h, the same set of pictures was acquired, the anterior
image taking about 20 min, with the patient in the same position.
The blank film used on the previous day to record the position of
the skin markers was positioned on the screen of the computer
again and the camera was positioned in such a way that the skin
markers of the 22-h image matched their position as recorded on
the blank film ofthe 10-minimage; thus, satisfactory initial patient
registration could be obtained and subsequently improved by
computer analysis. This is required for the correct application of
the change detection algorithm.
Significance probability mapping
The significance probability mapping (SPM) for this study was
based on a statistical pixel by pixel comparison between the 10-min
and the 22-h images. Before statistical pixel comparison an image
normalization or prewhitening stage is carried out. The image
normalization process ensures a significant pixel to pixel decorre-
lating effect and therefore the independence requirement of a
chosen statistical test is largely met (see Appendix, part 1, for the
formula). The derived map is called statistical scaling and is related
to the image processing techniques ofunsharp masking. A window,
five by five pixels in extent, has been chosen for the current
application. For the two homologous images, a small centralized
window size is typically five by five pixels square. For each of
these small subpopulations a parametric statistical test, the pooled
t-test, is used to test the significance of any difference in the mean
counts of the windowed pixel subset (see also Appendix, parts 2
and 3). The SPM parametric image is generated by this process.
The various P-values are presented as a colour table, so that the
resulting image is a colour map of P-values each indicating the
significance of the change that has occurred between the 10-min
and 22-h image.
Interpretation of scans
Planar and processed images were interpreted by two nuclear
medicine physicians who were unaware of the clinical, surgical
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Table 1 Comparison of 99mTc SM3 immune scan results with clinical and histopathological data
Patient Name Clinical Planar Probability map Pathology Result
number
B N B N B N B T size (mm) n Histology B N
2
3
4
5
6
HN
MOM
LS
MC
MD
MG
R
L
L
R
Rec
bxR
7 DG R
8 TC N
9 CS R
10 JW L
11 MM R
12 AS R
L
13 RH bx
R
14 SF bx
L
15 CH R
16 TM bxR
17
18
19
20
21
GS
EB
CMK
WH
NS
R
R
L
L
L
22 AB bx
R
23 JG L
R
24 KS R
25 DW R
- R + R;B4 +;N5 R;G1 21
- L - L;B5 +;N4 L;G2 21
+ L - L;B5 +;N3 L;G1 22
_ _
- - - R
- R - R;B5 - R;G3
bx:G1
- - R;B2 - no res
- - - R;B5 +;N5 R;G3 12
- - R;B5 R;G3 20
- R - R;B4 - R
- R - R;B5 - R;G2 18
- L + L;B5 +;N5 L;G3 23
+ R - R;B4 +;N5 bx*
- - + R;B3 +;N5 R;G2 17
- L + L;B4 +;N5 bx-
bx:G3 22
R - R;B5 - no res
- R R;B5 - papill
L - L;B5 - bx:G2
L:+ 22
- R - R;B5 N3 R;G3 13
bx:G2 15
- - R;B4 - R:+ 1.4
- R - R;B5 - R;G1 35
- - - R;B5 +;N5 R;G1 21
+ L - L;B4 +;N5 R;G2 25
- - - L;B5 +;N5 L;G1 15
- L - L;B5 - L;G2 3
+
20
R
L
R
R
bx:G1
- R;B4 - no res
- L;B5 - L;G3 21
- R;B5 - R;G3 15
- R;B5 - R;G2 13.5
- R;B5 +;N4 R;G2 20
R;B5
26 AN L + L - L;B5 +;N4 L;G2 38
27 MM R R - R;B5 - R;G3 13
1/16 Duct
5/15 Duct
0/7 Duct + lobul
0/9 Muc
0/1 Duct
DCIS
0/10 -
1/7 Duct
Duct
0/9 DCIS
0/7 Duct + lobul
3/19 Duct
ND Lobul + duct
5/21 Duct
ND Fibr
- Duct
0/18
1/14 Duct + lobul
0/22 Duct
Duct
0/25
0/2 DCIS
1/16 Duct
6/13 Duct
0/9 Duct
0/14 Duct
DCIS
DCIS
0/9
0/14 duct
0/12 lobul
0/14 duct
DCIS
5/14 duct
+
DCIS
papill
4/18 duct
+
DCIS
0/9 duct
28 AB L
29 MOC R
- - - L;B1
- - - R;B1
- L;G2 12
- R;G1 12
DCIS
0/11 duct
DCIS
0/9 duct
DCIS
Abbreviations: B, breast; N, nodes; Mx, mammography; PROB MAP, probability mapping; Histol, histology; R, right; L, left; Gl, 2, 3, grading of differentiation (Gl,
well-differentiated; G2, moderately differentiated; G3, poorly differentiated); B1-B5, grading of breast immune scan report; Nl-5, grading of node immune report;
TP, true positive; TN, true negative; FP, false negative; FN, false negative; bx, biopsy, DCIS, ductal carcinoma in situ; duct, ductal; lobul, lobular; muc, mucinous;
rec, recurrence; ND, not done; no res, no residual; papill, papilloma; * pt operated elsewhere, histology not available; fibr, fibrocystic changes with calcification.
Grading of reports: B1, Ni, Ri, normal; B2, N2, R2, equivocal-normal; B3, N3, R3, equivocal; B4, N4, R4, abnormal; B5, N5, R5, definitely abnormal.
and histological data. Results of the probability mapping were normal (the difference in the number ofcounts between the image
graded from 1 to 5, according to the colour map blue green/orange at 10 min and the image at 22 h was up to one standard deviation);
red/bright red related to the number of standard deviations of 3 meant 1-2 standard deviations; 4 probably abnormal (difference
difference between the two images: 1 (corresponding to the blue) was 2-3 standard deviations); 5 (corresponding to the bright red)
was considered normal; 2 meant that the result was probably was definitely abnormal. The difference in the number of counts
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TP TP
TP TP
TP FP
FN TN
TP TN
TN TN
TP TP
TP
TP TN
TP TN
TP FP
TP ND
FN TP
FP ND
FP TN
FP
TP FN
TP FP
FP TN
TP TN
TP TP
TP TP
TP FP
TP TN
FP TN
TP TN
TP TN
TP TN
TP TP
FP
TP TP
TP TN
FN TN
FN TN
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Figure 1 Patient number 10 (JW). 99mTc SM3 radioimmunoscintigraphy. Anterior views of the chest at 10 min (top left) and 24 h (top right). Change detection
probability map showing significant differences (bottom left) and key to outlines (bottom right). Planar images show cardiac blood pool and liver, and a small
blue focus can be seen in the region of the left breast at 24 h and possibly in the left axilla. The change detection map shows the significance of the differences
between the 24-h image and the 10-min image. P < 0.001 in red, P < 0.01 in orange, P < 0.05 in green and P > 0.05 in blue. A highly significant focal area of
increased uptake is seen in the left breast corresponding to the tumour, in the left axilla corresponding to involved nodes and in the internal mammary region on
the left (not sampled at surgery). Breast surgery confirmed a primary left ductal carcinoma and that 3 out of 19 nodes sampled from the left axilla were involved
between the image at 10 min and image at 22 h was more than 3
standard deviations. Findings from the probability mapping was
also compared with other areas ofnon-significant uptake, owing to
activity in blood vessels or to imperfect repositioning of the
patient during the 22-h image.
Areas above the brachial and subclavian arteries, even if the
change detection algorithm discovered significant increase with
time ofradiolabelled antibody, were not considered because ofthe
inability of the patient to control small head and neck movements
that cause artefacts in this region.
An increase in activity with time in the liver was usual, owing to
the uptake and metabolism of the antibody, so the organ was
isolated in a region of interest and ignored. Areas of negative
change such as the heart andbig vessels were also excluded. These
were isolated in regions ofinterest and not considered.
RESULTS
The clinical and imaging, surgical and histopathological data are
set out in Table 1. The investigated patients had 346 surgically
removed lymph nodes from 29 axillae (one patient, no. 11, was
operated in another hospital and histology was not made available
and the date excluded; another patient, no. 23, had bilateral
mastectomy with bilateral axillary clearance).
Toxicity
The radioimmunoscintigraphy was extremely well tolerated, with
no discomfort. No patient complained of later arthralgia, or rash,
and there was no serum sickness.
Imaging results
Immunoscintigraphic findings (planar images with and without
change detection algorithm with probability mapping) were
compared with the clinical examination and with histopathology
(29 axillae in 28 evaluable patients) (Figures 1 and 2).
Planar images of 29 axillary lymph node regions studied
showed 3 out of ten true positives and 18 out of 19 true negatives,
with seven out often false negatives and 1 false positive out of 19.
Sensitivity was 30%, specificity 95% and accuracy 72%.
Change detection algorithm with probability mapping of the 29
axillary lymph node groups showed nine out often true positives, 16
out of 19 true negatives, 3 out of 19 false positives and one false
negative out of ten. Sensitivity was 90%, specificity 84% and accu-
racy 86%. The three false positives in the axilla were due to a node
that had been called positive when it was due to tumour extension
(patient no. 15); movement artefact interpreted as node positive
(patient no. 20); and finding a node positive deep in axilla, which
may have been taken for tumoral venous invasion (demonstrated
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Figure 2 Patient number 24 (KS). 99mTc SM3 radioimmunoscintigraphy anterior chest views. Key as for Figure 1. Planar images show at 24 h some possible
blue activity in the region of the right breast. Change detection map shows highly significant uptake in the right breast, non-significant uptake in the left breast
and no uptake in either axilla. A primary ductal carcinoma was confirmed at surgery and none of 14 nodes was shown to be involved
subsequently at the histopathological examination - patient no. 3) or
may not have been included in the axillary clearance. The one false
negative was due to a micrometastasis in 1 out of 20 nodes sampled
(patient no. 14).
Planar images of 35 breast lesions in 29 patients (29 preopera-
tive breast cancers, two benign papillomas, three breasts studied
after the excisional biopsy, one breast with fibrocystic changes and
involution with calcification) showed 18 out of 29 true positives
(62% sensitivity), no true negatives, 10 out of 29 false negatives
and six false positives.
The change detection algorithm with probability mapping ofthe
breast showed 25 out of29 true positives (sensitivity 86%), no true
negative, six false positives and four false negatives. The six false
positives in the breast were due to: excisional biopsy performed
30-50 days before the scan (three patients: no. 6, no. 13 and no.
22); papilloma with areas of apocrine metaplasia, which showed
immunocytochemical uptake of SM3 in two patients (no. 14 and
no. 25); and fibrocystic changes and involution with calcification,
demonstrated after biopsing a breast area that was suspicious at
mammography, which showed uptake of SM3 (one patient, no.
12). The four false negatives in the breast were due to: mucinous
carcinoma (the abundant secretion of mucin may have prevented
the antibody from getting to the tumour (patient no. 4); an equiv-
ocal uptake (grade 3) was reported as negative in one patient (no.
12); and primary tumours (ductal carcinomas + ductal carcinoma
in situ) of 12 mm were missed both by the planar images and the
change detection algorithm (patients nos 28 and 29).
DISCUSSION
This pilot study had the specific aim of evaluating metastatic
involvement ofaxillary lymph nodes in patients with breast cancer
and, as a secondary aim, evaluating the uptake ofthe radiolabelled
antibody in the primary tumour. For this reason, the supine posi-
tion was chosen to be more appropriate for the study of the lymph
nodes rather than for breast imaging.
The key principles ofthe study can be summarized as follows:
* Specific uptake ofthe antibody increases with time, whereas
non-specific uptake decreases with time; this explains why the
10 min image, which reflects vascular activity and non-
specific uptake with no significant specific monoclonal anti-
body uptake, is important as a template with which to compare
the later images.
* Imaging with 99mTc gives a powerful signal ofantibody uptake
in spite ofthe background activity. The more potent the signal,
the higher the signal-to-noise ratio and the less the noise is
inherent in the signal (Britton and Granowska, 1987). SM3 is a
good antibody for studying breast cancer (Granowska et al,
1996) as well as ovarian cancer (Granowska et al, 1993).
Previous studies in ovarian cancer using 99mTc SM3 have shown
less than 20% human anti-mouse antibodies and no clinical reac-
tions (Granowska et al, 1990). They were not evaluated here.
SPM is the process of deriving a parametric image whose
elements contain the significance P-value that is returned after
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performing a parametric test between the pixels of the two images
being compared. There are two distinct approaches to SPM, i.e.
global linear regression and pixel by pixel statistical comparison.
The global linear regression approach uses a two-dimensional co-
occurrence matrix or scattergraph and has been used successfully
in ovarian cancer (Granowska et al, 1988).
Because of its limitations, a new approach was developed using
a SPM based on a statistical pixel by pixel comparison between
the 10 min and the 22-h images. The image normalization
(prewhitening) performed before the statistical pixel comparison,
besides aiding in the detection process directly, overcomes the
problem ofinterpixel correlation.
The change detection algorithm is essential for detecting
changes in uptake with time. A typical biological half-life ofclear-
ance of99mTc-labelled SM3 whole antibody from the blood is 24 h.
For a whole antibody and a typical compact, reasonably vascular,
tumour, about 75% of the total uptake would be expected to occur
in the first 12 h. Images taken at 10 min and 22-24 h cover, there-
fore, a long enough period for a significant increase in uptake to
occur over time.
In evaluating the results of the images of the uptake in the
lymph nodes produced by the change detection algorithm, atten-
tion was paid to the pretest likelihood of axillary node involve-
ment, that is considering the size of the primary tumour, whether
the nodes were palpable on the clinical examination (Table 1).
The results obtained in axillary nodes comparing radio-
immunoscintigraphy with surgical findings and histology in terms
ofsensitivity (90%) and specificity (84%) are encouraging. In this
series ofpatients, clinical evaluation of nodal status was poor. Of
five patients with palpable nodes, histology was positive in two,
negative in two and not done in one. A total of seven out of nine
patients with clinically impalpable nodes had a tumour present
(Table 1).
Misregistration led to one false-positive result. The registration
procedure has been improved. Provided the protocol is followed,
the change detection algorithm is not particularly sensitive to
movement. On the 10-min image, if a large background region is
used for each 5 x 5 pixel region and compared with a small tumour
within a region of 5 x 5 pixels at 22 h this will not be affected by a
misregistration of one or two pixels. Any major misregistration is
detected by 'negative shadows': negative deviations seen on the
edges of active areas such as blood vessels, the heart and the liver.
The minimum detectable signal was shown to be an absolute
tumour count of 37 c.p.s. per pixel over a typical background
count of 25 c.p.s. per pixel with the minimal detectable tumour to
background ratio of 1.46, which gives a difference significant at
P < 0.05. The basis ofthe calculation is shown in the Appendix.
Three patients (nos 6, 13 and 22), who had excisional biopsy of
the breast performed 30-55 days before the scan and who, at a
subsequent operation, were demonstrated to be free of residual
malignancy showed significant uptake of antibody in the area of
the excisional biopsy. The reason for this is not clear: one hypoth-
esis is that the uptake may be due to the new-grown tissue in the
area of the surgical scar, whose young cell-surface glycoproteins
may not have been entirely glycosylated and may therefore still
expose the antigenic epitope. Two patients (nos 14 and 25) with
images that were false positive forprimary breast cancer had some
areas of papillomatosis with apocrine metaplasia, which took up
the antibody, as described by Burchell et al (1987).
The study appears to be in line with the recent literature on the
topic. Tjandra et al (1989) reported immunolymphoscintigraphic
findings in 40 patients with histologically proven or cytologically
suspicious breast cancer. The authors conclude that, as involve-
ment of axillary lymph nodes is of importance as a prognostic
factor and as an indicator for adjuvant therapy, further improve-
ment in diagnostic accuracy is needed before axillary dissection
and histology can be replaced by immunolymphoscintigraphy
scanning of the axillae. They can not explain the mechanism of
non-specific uptake of antibody by normal lymph nodes or the
mechanisms ofaction of a second blocking antibody.
Schatten et al (1994) made use of two '231-radiolabelled mono-
clonal antibodies, one specific and the othernon-specific for breast
cancer, with a 1-week interval between injections. Comparisons of
both pictures, with possible specific and non-specific uptake, was
obtained. A typical pitfall of subcutaneous immunoscintigraphy is
described as the inaccessibility of the lymph nodes attributable to
the occlusion ofthe lymphatic vessels, which is frequently the case
when a metastasis breaks through the lymph node capsule.
Previous studies in breast cancer (Deland et al, 1979) with anti-
CEA antibodies are not ideal because CEA antigen is released by
the cancer cell and can be trapped in the draining lymph nodes,
which bind the antibody so that the node may appear positive in
imaging even when no cancer cells are present, as noted in
colorectal cancer (Granowska et al, 1989).
Preliminary results from McEwan et al (1994) in 53 patients
with breast cancer, with a 99mTc-labelled monoclonal antibody
(170 H.82), planar and SPET imaging show a sensitivity of 90%
and a positive predictive value of 95% for locoregional disease
(breast and axillary lymph nodes, many of which were palpable).
This differs from the patient studies reported here, which were
from a national screening programme, mostly with impalpable
axillary nodes (Table 1).
Apart from monoclonal antibodies, other radiopharmaceuticals
are being studied. 99mTc-MIBI (methoxy-isobutyl-isonitrile) is
being used in the evaluation of breast cancer and axillary lymph
nodes with good results (Khalkhali et al, 1994; Palmedo et al,
1996). However, muscle uptake of MIBI may interfere with the
evaluation of the axilla. Positron emission tomographic (PET)
scans showing increased '8FDG (fluorodeoxyglucose) uptake in
axillary nodes have a strong likelihood of detecting cancer,
although FDGuptake may also occur in reactive hyperplasia. Avril
et al (1995) evaluated the diagnostic accuracy of axillary PET
imaging in patients with recently detected breast tumours. I8FDG
PET showed a sensitivity of 72% and a specificity of 96%. Five
false-negative results were classified as pN1 at histology and
lymph node size was smaller than 2 cm. The conclusion was that
axillary node dissection was still required, even in patients with
negative axillary PET scans, and further improvements in spatial
resolution were required to increase sensitivity ofPET imaging. In
the study by Wahl et al (1991), ten out of ten primary tumours
were visualized and FDG scanning was reliable in the detection of
lymph node and distant metastases. Nieweg et al (1993), found
that monitoring treatment with PET FDG in 10 out of 11 patients
with primary breast cancer the tumour was visualized. In all five
patients with increased uptake in the lymph nodes, pathological
proof of metastatic cancer was found. Adler et al (1993) correctly
found ten out of ten axillary nodes to be negative and nine out of
ten to be positive using FDG PET; however, in the positive axillae
five out of those nine had 10-26 nodes involved that were prob-
ably clinically evident, although this was not stated.
These preliminary results with radioimmunoscintigraphy allow
the following conclusions:
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a. planar images are insufficiently sensitive for the detection of
involved impalpable or small axillary lymph nodes; and
b. 99mTc-labelled SM3 in conjunction with probability mapping
appears a promising technique for the imaging ofthe axilla:
clinically negative lymph nodes can be shown correctly posi-
tive; and clinically positive nodes can be shown correctly
negative. A good specificity is particularly important because
false negatives are not well considered, whereas false positives
are much better tolerated.
Previous knowledge about the involvement of axillary lymph
nodes should enable the extent ofsurgery to be tailored to the indi-
vidual woman. A more generous use of axillary surgery could be
advised in node-positive patients and a full axillary clearance may
be avoided in node-negative patients, in whom sentinel node
sampling at surgery might be sufficient (Krag et al, 1993). The
patient could then be spared the complications deriving from axil-
lary node dissection. This study with 99mTc SM3 and the use of
a change detection algorithm is encouraging in the pursuit of
this goal.
The results obtained suggest the prospective evaluation of a
surgical strategy of axillary clearance for patients with positive
lymph nodes at the 99mTc SM3 immunoscintigraphy with change
detection statistical processing, and axillary sampling in patients
with negative lymph nodes.
ACKNOWLEDGEMENTS
We are grateful to Miss Nish Fernando and Mrs Cherry Sebastian
for the acquisition of the scans, and to Mrs Margaret Sullivan for
her help in the recruitment of the patients. This work has been
supported by a grant from Cytogen Corporation, USA. We also
acknowledge the support of the Imperial Cancer Research Fund
and are grateful for the use of the facilities of the St
Bartholomew's Hospital Foundation for Research. We thank espe-
cially Dr Joy Burchell and Dr Joyce Taylor-Papadimitriou for
making available to us their knowledge and expertise on SM3.
REFERENCES
Adler LP, Crowe JP, Al-Kaisai NK and Sunshine JL (1993) Evaluation ofbreast
masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Radiology 187: 743-750
Avril N, Janicke F, Dose J, Ziegler S, Bense S, Zincke M, Romer W, Weber W,
Herz M and Schwaiger M (1995) Evaluation ofaxillary lymph node
involvement in breast cancer patients using F-18 FDG PET. EurJNucl Med
22: 733
Biersack HI (1995) Mammoscintigraphy with Tc-99m MIBI in patients with
suspicious breast nodules: a comparison of planar and SPECT imaging
techniques. Eur JNucI Med 22: 725
Bischof-Delaloye A, Delaloye B, Buchegger F, Gilgien W, Studer A, Curchod S,
Givel JC, Mosimann F, Pettavil J and Mach J-P (1989) Clinical value of
immunoscintigraphy in colorectal carcinoma patients: a prospective trial.
JNucl Med 30: 1646-1656
Britton KE and Granowska M (1987) Radioimmunoscintigraphy in tumour
identification. Cancer Surv 6: 1247-1267
Britton KE and Granowska M (1993) The present and the future ofradiolabelled
antibodies in oncology. Ann Nucl Med 7: 127-132
Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R and
Lamport D (1987) Development and characterization of breast cancer reactive
monoclonal antibodies directed to the core protein ofthe human milk mucin.
Cancer Res 47: 5476-5482
Burchell J and Taylor-Papadimitriou J (1993) Effect ofmodification ofcarbohydrate
side chains on the reactivity ofantibodies with core-protein epitopes of the
MUC 1I gene product. Epith Cell Bi 2:155-162
Deckers PJ (1991) Axillary dissection in breast cancer: when, why, how much, and
for how long? Are these operations soon to be extinct? JSurg Oncol 48:
217-219
Deland FH, Kim BE, Corgan RL, Casper FS, Primus FJ, Spremulli E, Estes N and
Goldenberg DM (1979) Axillary lymphoscintigraphy by radioimmunodetection
ofcarcino-embryonic antigen in breast cancer. JNucl Med 20: 1243-1250
Doerr RJ, Abdel-Nabi H, Baker JM and Steinberg S (1990) Detection ofprimary
colorectal cancer using indium- Ill monoclonal antibody B72.3. Arch Surg
125: 1601-1605
Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham L, Deutsch M,
Montegue E, Margolese R and Foster R (1985) Ten year results of a
randomized clinical trial comparing radical mastectomy and total mastectomy
with or without radiation. N Engl JMed 312: 674-681
Girling A, Bartkova J, Burchell J, Gendler S, Gillet C and Taylor-Papadimitriou J
(1989) A core protein epitope ofthe polymorphic epithelial mucin detected by
the monoclonal antibody SM3 is selectively exposed in a range ofprimary
carcinomas. Int J Cancer 43: 1072-1076
Goldenberg DM and Larson SM (1992) Radioimmunodetection in cancer
identification. JNucl Med33: 803-814
Granowska M, Nimmon CC, Britton KE, Crowther M, Mather SJ, Slevin ML and
Shepherd JH (1988) Kinetic analysis and probability mapping applied to the
detection ofovarian cancer by radioimmunoscintigraphy. JNucl Med 29:
599-607
Granowska M, Jass JR, Britton KE and Northover JMA (1989) A prospective study
ofthe use of IllIn-labelled monoclonal antibody against carcinoembryonic
antigen in colorectal cancer and of some biological factors affecting its uptake.
Int J Colorect Dis 4: 97-108
Granowska M, Mather SJ, Jobling T, Naeem M, Birchall J, Taylor Papadimitriou J,
Shepherd J and Britton KE (1990) Radiolabelled stripped mucin, SM3,
monoclonal antibody for immunoscintigraphy ofovarian tumours. Int J Biol
Mark 5: 89-96
Granowska M, Britton KE, Mather SJ, Lowe DG, Ellison D, Bomanji J, Birchall J,
Taylor Papadimitriou J, Hudson CR and Shepherd JH (1993)
Radioimmunoscintigraphy with technetium-99m labelled monoclonal antibody,
SM3, in gynaecological cancer. Eur JNucl Med 20: 483-488
Granowska M, Biasoni L, Carroll MJ, Howell R, Mather SJ, Ellison D, Granowski A
and Britton KE (1996) Breast cancer 9'9mTc SM3 Radioimmunoscintigraphy.
Acta Oncol 35: 319-321
Harris JR and Osteen RT (1985) Patients with early breast cancer benefit from
effective axillary treatment. Breast Cancer Res Treat 5: 17-21
Khalkhali I, Mena I, Jouanne E, Diggles L, Venegas R, Block J, Alle K and Klein S
(1994) Prone scintimammography in patients with suspicion ofbreast cancer.
JAm Coll Surg 178: 491-497
Krag DN, Weaver DL, Alex JC and Fairbank JT (1993) Surgical resection and
radiolocalization ofthe sentinel lymph node in breast cancer using a gamma
probe. Surg Oncol 2: 335-340
McEwan AJB, Akram I, Boniface G, Golberg L, McQuarrie SA, Golberg K,
Amyotte G, Hornig B, Noujaim AA and MacLean GD (1994) Tc-99m
monoclonal antibody in the evaluation oflocoregional disease in patients with
breast cancer. EurJ Nucl Med 21 (suppl.): S15
Massuger LFAG, Keenemans P, Claessens RAMJ et al (1990) Immunoscintigraphy
ofovarian cancer using indium-1Il labelled OV-TL3 F(ab')2 monoclonal
antibody. JNucl Med 31: 1802-1810
Mather SJ and Ellison D (1990) Reduction-mediated Tc-99m labelling of
monoclonal antibodies. J Nucl Med 31: 692-697
Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE and Tilbury RS
(1993) Positron Emission Tomography with fluorine-I 8-deoxyglucose in the
detection and staging ofbreast cancer. Cancer 71: 3920-3925
Palmedo H, Grunwald F, Bender H, Schomburg A, Mallmann P, Krebs B and
Biersack HJ (1996) Scintimammography with Technetium-99m
methoxyisobutylisonitrile: comparison with mammography and magnetic
resonance imaging. Eur JNucl Med 23: 940-946
Silverstein MJ, Giersone D, Waisman JR, Senofsky GM, Colbum WJ and
Gamagami P (1994) Axillary lymph node dissection forTIa breast carcinoma
- Is it indicated? Cancer 73: 664-667
Schatten C, Bawada M, Mandeville R, Enzelsberger H, Angelberger P,
Czerwenka K, Kubista E and Pateisky N (1994) Combined use of 123-I
labelled BCDF9 and 4C4 monoclonal antibodies with dissimilar specificity
for breast cancer: implication for detection limits of
immunolymphoscintigraphy in the assessment ofaxillary lymph nodes. Nucl
Med Comm 15: 422-429
Tjandra JJ, Russell IS, Collins JP, Andrews JT, Lichtenstein M, Binns D and
McKenzie IFC (1989) Immunolymphoscintigraphy for the detection of lymph
node metastases from breast carcinoma. Cancer Res 49: 1600-1608
C Cancer Research Campaign 1998 British Journal ofCancer (1998) 77(1), 131-138138 L Biassoni et al
Wahl RL, Cody RL, Hutchins GD and Mudgett EE (1991) Primary and metastatic
breast carcinoma: initial clinical evaluation with PET with the radiolabelled
glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179: 765-770
Wahl R (1992) Monoclonal antibodies in nuclear medicine. In Nuclear Medicine
Annual 1992, Freeman L (ed.), Raven Press: New York
APPENDIX
Statistical tumour detection
(1) Image normalization
The normalization process takes the form of a transformation
described by the expression:
J(x,y)= Si (I(x,y)-m,(x,y))+ mj (A)
where m1 and S, are the measured local mean and standard devia-
tion of the input image I, measured over a local n x n window
centred at the current pixel position x,y and where mj andS. are the
required mean and standard deviation of the output image J.
(2) The pooled t-test
The pooled t-test takes the form:
= (m,I - m2)
sp'' +1 (A2)
n, n,
where the pooled measured variance Sp is given by:
S _ S,(n, 1) +S2(n2- 1)
p n +n2-2 (A3)
and ml and m2 are the means for pixel groups 1 and 2 respectively,
n, and n2 are the corresponding number of degrees of freedom,
which in this case correspond to the number of pixels within the
current data window, andSi and S, are the corresponding sample
standard deviations.
In the case of the current task of tumour signal detection, the
hypothesis being tested is that the current pixel of interest is
located within an area ofsignificant change manifested by a differ-
ence in the local mean pixel counts, i.e.
HO: ml - M2 =0
Hi m1 -iMn >0.
The null hypothesis that a significant difference or tumour signal
is not present (HO) is rejected when, for (n1 + n2 - 2) degrees of
freedom of the t distribution, the level of significance or P-value
returned by the test is greater than a prescribed level ofsignificance;
for example, for a P-value of0.005 and a 5 x 5 data window giving
rise to 25 + 25 -2 degrees offreedom, a value for the t distribution
greater than or equal to 2.42 would indicate a P-value of 0.005, a
highly significant result, and the null hypothesis HO would be
rejected, indicating a significant change has occurred.
(3) Minimum detectability
The question of whether the counts within two homologous
regions of interest or data windows are significantly different is
equivalent to determining if the means of two distributions are
significantly different. The variance of radioactive data counting
follows that described by Poisson statistics, but ifthe mean number
ofcounts detected is >>1, then the normal or Gaussian distribution is
a good approximation to the Poisson distribution. In this case, the
normal distribution's variance will be equal to the mean.
Taking the normal distribution as being valid for the mean
counts encountered in this application, the significance of the
difference between the two mean counts m, and m2 respectively is
given by:
m2-im
'lvar(m,) + var (m,n)
where Z has a unit normal distribution with a mean of zero and a
variance of 1.
We may define a tumour to background ratio R as:
1 (m2-ml8
m,I m, m
Thus, we have:
Z = Rml
Xvar(mi2) + var (ml)
We may use this expression to estimate the minimum detectable
tumour to background ratio for a particular level of significance or
P-value, for example Z takes the value of 1.64 corresponding to a
P-value of0.05. Therefore, ifwe make the simplifying assumption
ofequal variances and solving for R we have:
R 2 1.64-Xg~va(m,)
ml
For a typical 128 x 128 background reference image, and for a
window size of 5 x 5 pixels, m, has a mean value of25 counts and
the minimum tumour uptake ratio to achieve detection at the
P = 0.05 level of significance is 1.46.
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